Cheol Lee J, Hung JY, Kim YC, Chang GC, Soo Yoo S, Yang SH, Davis KL, Nagar SP, Taylor A, Yong Lee S, Shih JY. Real-world treatment patterns in patients with EGFR mutation-positive NSCLC receiving a first line, first- or second-generation EGFR tyrosine kinase inhibitor in South Korea and Taiwan. Asian Pac J Cancer Bio. 2021 May 20;6(2). doi: 10.31557/APJCB.2021.6.2.123-132
Graham J, Earnshaw S, Lim J, Luthra R, Borker R. Cost-effectiveness of afatinib versus erlotinib in the first-line treatment of patients with metastatic non-small cell lung cancer with EGFR Exon 19 deletion mutations. JCP. 2016 May;2(4):31-9.
Fleming AD, Philip S, Goatman KA, Sharp PF, Olson JA. Automated clarity assessment of retinal images using regionally based structural and statistical measures. Med Eng Phys. 2012 Sep 1;34(7):849-59. doi: 10.1016/j.medengphy.2011.09.027
Knoll S, Jochum D, Talbird S. Comparative cost benefit analysis of two new Pneumococcal Conjugate Vaccines (PHiD-CV and PCV-13). Klin Padiatr. 2010 Jun 1;222(Suppl 1):S51-2.